$INFI

Infinity Pharmaceuticals Inc.

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$1.37 ▼-8.054%

Extented Hours

VOLUME

930,739

DAY RANGE

1.41 - 1.52

52 WEEK

0.4605 - 3.89

Join Discuss about INFI with like-minded investors

profile
@DarkPoolAlgo #Dark Pool Charts
recently

U.S. futures are holding steady, only moderately lower from yesterday’s closing all-time highs for the major averages as investors brace for the FOMC meeting, with results expected tomorrow afternoon. Bitcoin prices surging to highs, up over 4% around $63,400 in another broad spike for crypto assets; Ethereum +3.25% at $4,450. House Speaker Pelosi is planning to go ahead with plans to vote this week on President Biden’s two bills even though Democratic moderates are echoing Senator Manchin’s complaints that they don’t know full cost & economic impact. In corporate news, JNJ, TEVA, ENDP and ABBV win the first case for pharmaceutical companies in the four-year litigation over the drugs in a $50B opioid litigation case. In commodity prices, gold holds below $1,800, oil is little changed around $84 per barrel and Wheat hit $8.00 a bushel Monday, highest levels since 2012 as world reserves declined following extreme weather. The Aussie dollar drops and the curve bull steepens after the RBA scraps its April 2024 yield target and signals openness to earlier rate hikes. Tesla $TSLA falls over 4%, is falling off a record high close of $1,208.59 – follows tweet from CEO Musk overnight saying there has been no contract signed yet with Hertz and that the Hertz deal has zero effect on Tesla’s economic. Wall Street’s main indexes notched record closing highs again on Monday, adding to the big totals in October as Tesla $TSLA shares surged and the energy sector gained on rising oil prices while investors looked ahead to a major Federal Reserve meeting later in the week. The Dow Jones Industrial Average briefly eclipsed 36,000 points for the first time before slipping just below. Along with the barrage of earnings again this week, the Federal Reserve is expected to approve plans to scale back its $120 billion monthly bond-buying program on Wednesday. The small-cap Russell 2000 index was a standout, rising 2.7% for its biggest daily percentage gain since late August. Economic data was mixed as the ISM U.S. manufacturing activity slowed in October, with all industries reporting record-long lead times. In Asian markets, The Nikkei Index slipped -0.43% to 29,520, the Shanghai Index dropped -1.1% to 3,505, and the Hang Seng Index fell -0.22% to 25,099. In Europe, the German DAX is up +0.4% at 15,875, while the FTSE 100 declines around -0.6% below 7,250. Events Calendar for Today · 7:45 AM ET ICSC Weekly Retail Sales · 8:55 AM ET Johnson/Redbook Weekly Sales Earnings Calendar: · Earnings Before the Open: AME, APO, ARCB, AVNS, BBGI, BCC, BHC, BLD, BLMN, CEIX, CLW, CMI, COP, CRSR, CTLT, DD, EL, EPD, ESPR, ETN, EXLS, EXPD, EXTR, GNRC, GPN, HEES, HEP, HSC, HSIC, IART, IDXX, INCY, IPGP, IT, KKR, LCII, LDOS, LEA, LGIH, LPX, MIME, MLM, MMP, MPC, MPLX, MYGN, NRZ, NXST, NYMT, OMCL, PFE, PINC, RL, ROK, SABR, SAGE, SEE, TMX, TNC, UAA, VAL, WEC, WLK, XHR, XYL ZBRA · Earnings After the Close: ACT, AFG, AIZ, AKAM AMGN, ANDE, ATVI, AWK, AYX, BFAM, BGFV, BKH, BRY, BXC, CASA, CDK, CERS, CHK, COUR, CRK, CSLT, CZR, DCO, DCPH, DEI, DENN, DOX, DRRX, DVN, EGHT, EIX, ENLC, EXAS, EXEL, FMC, FNF, FRSH, GAIN, GNW, GPOR, HALO, HCC, HLF, HRB, HURN, INFI, INSP, KAI, KAMN, KAR, LPI, LSCC, LSI, LYFT, MANT, MDLZ, MG, MGNX, MOD, MRCY, MTCH, NP, NSA, OKE, OVV, PAA, PAGP, PAYC, PKI, PRO, PRTS, PRU, RAMP, RARE, RCKY, RM, RRR, SGRY, SKY, SRC, STE, TCS, TMUS, TVTY, UIS, UNM, VECO, VOYA, VRSK, WTTR, WU, ZG Other Key Events: · China Caixin Services PMI for October · Wolfe Research Wealth Symposium, 11/2-11/3 $virtual · Senator Manchin says he is prepared to support a Build Back Better plan that combats inflation, is fiscally responsible, and will create jobs. The plan the House is finalizing meets those tests-it is fully paid for, will reduce the deficit, and brings down costs for health care, child care, elder care, and housing

71 Replies 8 👍 10 🔥

profile
@dros #droscrew
recently

+Initiations 10/18: $AKA $ARBK $ATAI $BRLT $ESMT $FRSH $INFI $JG $NRDY $OLED $RBOT $RELY $SGRY $SOVO $STER $THRN $TOST $TRUP $WAL

40 Replies 13 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

$INFI new highs

118 Replies 7 👍 9 🔥

profile
@maletone #StockTraders.NET
recently

$INFI games yesterday got to 2.50s

143 Replies 7 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

watchlist: $DLPN, $Xbio, $INFi, $XCUR, $apt....$FLGC if it gaps up and gets volume

106 Replies 9 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

hope they keep $INFI up or runnit up into Ah's

51 Replies 13 👍 12 🔥

profile
@Chano #StockTraders.NET
recently

$INFI nuts

61 Replies 6 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$COCP reminds me of $INFI yesterday

123 Replies 12 👍 7 🔥

profile
@maletone #StockTraders.NET
recently

$INFI you dog

56 Replies 6 👍 8 🔥

profile
@maletone #StockTraders.NET
recently

$INFI yes c!!!

115 Replies 10 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

please $INFI run

78 Replies 14 👍 12 🔥

profile
@Math #StockTraders.NET
recently

$INFI maybe fade into close

112 Replies 6 👍 7 🔥

profile
@Chano #StockTraders.NET
recently

$INFI also getting crazy

96 Replies 15 👍 12 🔥

AN
@andres168 #StockTraders.NET
recently

$infi looks nice for a pop

124 Replies 11 👍 10 🔥

profile
@Chano #StockTraders.NET
recently

$INFI man! that turd not giving up!

101 Replies 15 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

covered some more $INFI

112 Replies 11 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

covered some more $INFI 2.18

98 Replies 9 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

$INFi spot of interest is 2.35 - 2.34's need s to break that and vwap

65 Replies 10 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

will watch $INFI for vwap fails

124 Replies 13 👍 15 🔥

profile
@Chano #StockTraders.NET
recently

$INFI kicked me out on the way up when it broke the 2.40s

113 Replies 10 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

$infi fails

144 Replies 9 👍 12 🔥

BR
@brAli #StockTraders.NET
recently

infi super thick

150 Replies 14 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

lets see if $INFI can get going

100 Replies 6 👍 7 🔥

SO
@soheil.n #StockTraders.NET
recently

watches: $GRVI, $INTZ, $INFI

90 Replies 6 👍 9 🔥

profile
@Chano #StockTraders.NET
recently

$INFI fresh of the oven ATM

147 Replies 13 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$infi on watch

111 Replies 7 👍 11 🔥

Key Metrics

Market Cap

136.60 M

Beta

2.09

Avg. Volume

713.66 K

Shares Outstanding

89.28 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-01

Next Dividend Date

Company Information

Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings.

CEO: Adelene Perkins

Website:

HQ: 1100 Massachusetts Ave Ste 4 Cambridge, 02138-5241 Massachusetts

Related News